Cover storyWHO lists first molecular diagnostic for Ebola Bundibugyo virus under EUL, seven weeks after PHEIC declaration over the DRC outbreak.
FDA grants Sanofi concurrent annual approval for Fluzone and Fluzone High-Dose, confirming 2026–27 seasonal authorization under STN BL 103914.
FDA approves FluLaval Quadrivalent for 2026–2027 season; lot release and GMP compliance timelines now active for ID Biomedical.
FDA approves Seqirus Flucelvax for 2026–2027 season on July 1, continuing annual cell-based influenza vaccine approval cycle.
Glenmark moves a HER2-targeted ADC into Phase 3 for platinum-resistant ovarian cancer, raising GMP and process validation considerations for ADC manufacturing at scale.
Syngene names Siddharth Mittal MD and CEO; his 13-year CFO tenure at Biocon shapes expectations for CDMO capacity and partnership strategy.
20260622153015.png&w=1920&q=75)
Interview
Interview
InterviewQ&A-driven breakdowns of the decisions, trade-offs and numbers behind real projects.
Q&A
Q&A
Q&A
Appointments & peopleSep 25, 2024
43633:20
5610:0020250626204711.webp&w=1920&q=75)
60000:00
28000:00
31000:00Podcast
Sep 16
Sep 28From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Evaluation frameworks that turn a crowded market into a shortlist you can defend.
Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
